IgA nephropathy
Conditions
Interventions
Sponsors
The First Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age =18 years; 2. Histopathological confirmation of IgA nephropathy (IgAN) based on renal biopsy; 3. Received standardized follow-up at participating tertiary Grade A hospitals within the study time window, with complete clinical data available; 4. Presence of persistent proteinuria at baseline (urine protein =1+ by dipstick or 24-hour urinary protein =0.5 g/day); 5. Received standard supportive therapy, including but not limited to renin–angiotensin–aldosterone system (RAAS) inhibitors; 6. Patients in the Nefecon treatment group must have received Nefecon in addition to conventional supportive therapy, with a treatment duration of =6 months; 7. Patients in the control group did not receive Nefecon during the same study period.
Exclusion criteria
Exclusion criteria: 1. Secondary glomerular diseases, including but not limited to systemic lupus erythematosus, cirrhosis-related nephropathy, hepatitis B- or C-associated glomerulonephritis, infection-related glomerulonephritis, systemic vasculitis, ANCA-associated vasculitis, and Henoch–Schönlein purpura nephritis; 2. Concomitant other primary glomerular diseases or pathological findings indicating non–IgA-dominant glomerular lesions; 3. Incomplete renal biopsy pathological data or inability to establish a definitive diagnosis; 4. Baseline eGFR <30 mL/min/1.73 m², or progression to end-stage kidney disease (ESKD) requiring maintenance dialysis or prior kidney transplantation; 5. Severe dysfunction of major organs such as the heart, liver, or lungs, or presence of active infection, malignancy, or other conditions that may significantly affect prognosis; 6. Follow-up duration less than 6 months or missing key clinical or laboratory data; 7. Pregnant or breastfeeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proteinuria;Estimated Glomerular Filtration Rate;Adverse Event; | — |
Countries
China
Contacts
Public ContactZhao Hongwen
The First Affiliated Hospital of Army Medical University
Outcome results
None listed